We investigated whether a triple combination therapy comprizing anti-PD-1, TLIF-PTT, and FlaB-Vax could induce more sustained tumor suppression and better therapeutic outcomes in the orthotopic Her2/neu breast cancer model (figure 6A). The gene discussed is ERBB2; the disease is breast carcinoma.